Minerva Neurosciences reported $3M in Selling and Administration Expenses for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 81.67M 15.12M
Adma Biologics ADMA:US $ 13.87M 631.53K
ALKERMES ALKS:US 136.21M 2.97M
Arena Pharmaceuticals ARNA:US $ 30.3M 1.63M
AstraZeneca AZN:LN 2.99B 412M
Biocryst Pharmaceuticals BCRX:US $ 34.99M 8.67M
Bristol Myers Squibb BMY:US $ 1.79B 95M
Dynavax Technologies DVAX:US $ 26.93M 5.85M
Eli Lilly And LLY:US $ 1.58B 107.8M
Esperion Therapeutics ESPR:US $ 39.26M 7.05M
GlaxoSmithKline GSK:LN 2.5B 6M
Halozyme Therapeutics HALO:US $ 13.17M 848K
IONIS PHARMACEUT IONS:US $ 31M 25.46M
Johnson & Johnson JNJ:US $ 6B 73M
Kindred Biosciences KIN:US 5.87M 1.18M
Marinus Pharmaceuticals MRNS:US 9.45M 2.62M
Merk MRK:US $ 2.27B 9M
Minerva Neurosciences NERV:US $ 3M 437.6K
Neurocrine Biosciences NBIX:US $ 154.6M 11.4M
Novartis NOVN:VX 3.6B 109M
Novavax NVAX:US $ 77.79M 4.63M
Pfizer PFE:US $ 2.73B 61M
Takeda 4502:JP 212.01B 7.83B
Vanda Pharmaceuticals VNDA:US $ 32.46M 4.11M